Multiple Sclerosis, Relapsing-Remitting
Information
- Disease name
- Multiple Sclerosis, Relapsing-Remitting
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02914964 | Active, not recruiting | N/A | Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study | August 2016 | January 26, 2025 |
| NCT03963375 | Active, not recruiting | Phase 4 | Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis | October 28, 2019 | May 30, 2025 |
| NCT03535298 | Active, not recruiting | Phase 4 | Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS | January 3, 2019 | September 2030 |
| NCT05605782 | Active, not recruiting | A Post-Authorization, Long-term Study of Ozanimod Real-world Safety | June 30, 2022 | December 31, 2032 | |
| NCT04261790 | Active, not recruiting | Phase 4 | Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis | August 1, 2020 | July 1, 2025 |
| NCT04220814 | Active, not recruiting | N/A | Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis | November 3, 2020 | December 31, 2025 |
| NCT05417269 | Active, not recruiting | Phase 1/Phase 2 | IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study | April 12, 2022 | December 31, 2025 |
| NCT03979456 | Active, not recruiting | Phase 3 | RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS | July 4, 2018 | June 1, 2025 |
| NCT05902429 | Active, not recruiting | Phase 4 | Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients | April 28, 2021 | August 2024 |
| NCT00112034 | Completed | Phase 4 | AVONEX® Combination Trial - "ACT" | June 2003 | May 2007 |
| NCT00206648 | Completed | Phase 4 | An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS | March 2003 | October 2005 |
| NCT00213135 | Completed | Phase 3 | A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) | April 2005 | November 2008 |
| NCT00220779 | Completed | Phase 2 | Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis | December 2002 | February 2005 |
| NCT00228397 | Completed | Phase 2 | Study Evaluating CCI-779 in Relapsing Multiple Sclerosis | November 2003 | November 2005 |
| NCT00235989 | Completed | Phase 2 | Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis | June 2003 | January 2008 |
| NCT00242177 | Completed | Phase 1 | Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability | October 2003 | October 2005 |
| NCT00276341 | Completed | Phase 3 | Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis | August 26, 2003 | December 8, 2005 |
| NCT00292253 | Completed | Phase 3 | Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects | January 2001 | December 2002 |
| NCT00292266 | Completed | Phase 3 | A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS) | November 1999 | June 2002 |
| NCT00306592 | Completed | Phase 3 | Natalizumab Re-Initiation of Dosing | March 2006 | February 2008 |
| NCT00441103 | Completed | Phase 3 | A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis | December 2006 | February 2009 |
| NCT00459667 | Completed | Phase 3 | BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose | May 2007 | March 2008 |
| NCT00461396 | Completed | Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron | May 2007 | November 2009 | |
| NCT00530348 | Completed | Phase 3 | Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One | August 2007 | April 2011 |
| NCT00548405 | Completed | Phase 3 | Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two | October 2007 | September 2011 |
| NCT00587691 | Completed | Phase 1/Phase 2 | Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis | July 2002 | December 2008 |
| NCT00675883 | Completed | COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS | May 2008 | December 2011 | |
| NCT00676715 | Completed | Phase 2 | A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis | July 17, 2008 | November 8, 2023 |
| NCT00888277 | Completed | Bayer/Cognitive Assessments With Multiple Sclerosis Subjects | May 2009 | January 2010 | |
| NCT00930553 | Completed | Phase 3 | An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab | August 2009 | February 2016 |
| NCT01075880 | Completed | Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® | May 2009 | June 2013 | |
| NCT01080001 | Completed | A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina | August 2008 | November 2012 | |
| NCT01108887 | Completed | An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. | September 2009 | January 2013 | |
| NCT01110993 | Completed | An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF) | November 2010 | September 2013 | |
| NCT01112345 | Completed | An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters | December 2009 | September 2012 | |
| NCT01116427 | Completed | Phase 2 | A Cooperative Clinical Study of Abatacept in Multiple Sclerosis | September 2010 | February 2015 |
| NCT01141751 | Completed | An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy | September 2005 | June 2011 | |
| NCT01142466 | Completed | Phase 4 | A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone | December 2005 | January 2010 |
| NCT01142583 | Completed | A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis | July 2006 | August 2009 | |
| NCT01143441 | Completed | Phase 1 | Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS) | May 13, 2010 | August 11, 2017 |
| NCT01158183 | Completed | Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis | July 2007 | September 2009 | |
| NCT01279876 | Completed | Phase 2 | Melatonin in Relapsing-Remitting Multiple Sclerosis Patients | October 2010 | February 2014 |
| NCT01392872 | Completed | N/A | Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant | November 2009 | January 2016 |
| NCT01414634 | Completed | Phase 1/Phase 2 | Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells | February 2010 | October 2012 |
| NCT01416363 | Completed | Phase 1 | Healthy Volunteer Study Using 3 Different Formulations of Firategrast | May 20, 2011 | September 17, 2011 |
| NCT01417312 | Completed | N/A | Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients | July 2011 | January 2013 |
| NCT01420055 | Completed | Phase 4 | Fingolimod -Response According to Coping - Evaluation | August 2011 | June 2013 |
| NCT01424462 | Completed | Phase 1 | Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place. | April 19, 2010 | July 6, 2010 |
| NCT01431937 | Completed | Phase 1 | Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers | October 10, 2010 | March 29, 2011 |
| NCT01466322 | Completed | Phase 1 | A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. | December 22, 2010 | February 15, 2011 |
| NCT01470521 | Completed | Phase 2 | Worms for Immune Regulation of Multiple Sclerosis | December 2011 | January 2016 |
| NCT01591551 | Completed | Phase 4 | NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness | March 2012 | August 2013 |
| NCT01628315 | Completed | Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study | March 2009 | December 2014 | |
| NCT01667796 | Completed | N/A | Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health | November 2010 | March 2014 |
| NCT01772199 | Completed | Phase 2 | Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis | February 2013 | September 2014 |
| NCT01909492 | Completed | Measurement of Relaxin Peptide in Multiple Sclerosis (MS) | September 20, 2013 | October 5, 2023 | |
| NCT02019550 | Completed | Phase 4 | Rebif® Rebidose® Versus Rebiject II® Ease-of-Use | March 2014 | January 2016 |
| NCT02040298 | Completed | Phase 2 | Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis | January 2014 | April 2016 |
| NCT02064816 | Completed | Phase 4 | A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis | May 31, 2014 | April 30, 2016 |
| NCT02275741 | Completed | Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis | October 2009 | November 2016 | |
| NCT02280876 | Completed | Phase 1/Phase 2 | Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS) | January 2012 | May 2015 |
| NCT02305264 | Completed | N/A | Imaging of Intracerebral Inflammation in MS | March 19, 2012 | September 10, 2018 |
| NCT02315872 | Completed | Phase 3 | ACTH for Fatigue in Multiple Sclerosis Patients | May 22, 2015 | December 13, 2018 |
| NCT00027300 | Completed | Phase 3 | Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis | November 2001 | January 2005 |
| NCT00030966 | Completed | Phase 3 | Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis | January 2002 | December 2005 |
| NCT00050778 | Completed | Phase 2 | A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis | December 2002 | January 2010 |
| NCT00067327 | Completed | Phase 2 | Treatment of Multiple Sclerosis Using Over the Counter Inosine | February 2002 | September 2005 |
| NCT00071838 | Completed | Phase 2 | Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis | October 30, 2003 | August 16, 2011 |
| NCT00076934 | Completed | Phase 1 | Safety of RG2077 in Patients With Multiple Sclerosis | January 2003 | February 2006 |
| NCT00097331 | Completed | Phase 2 | Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis | September 2004 | July 2006 |
| NCT00097760 | Completed | Phase 2 | Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis | June 2003 | March 2004 |
| NCT00099502 | Completed | Phase 3 | BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients | November 2003 | August 2007 |
| NCT02403570 | Completed | Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis | February 2015 | December 31, 2016 | |
| NCT02410200 | Completed | Phase 2 | Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS | September 30, 2015 | September 23, 2016 |
| NCT02419378 | Completed | Phase 4 | Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | June 2015 | November 2020 |
| NCT02461069 | Completed | Phase 4 | Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis | May 6, 2015 | May 7, 2018 |
| NCT02471560 | Completed | Phase 4 | Tecfidera and the Gut Microbiota | November 6, 2015 | June 12, 2017 |
| NCT02493049 | Completed | Phase 2 | Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS) | August 2015 | February 2019 |
| NCT02506751 | Completed | Phase 1 | Open-label Study of Liothyronine in MS | July 2015 | September 18, 2017 |
| NCT02515695 | Completed | Phase 1 | Phase I BP Interferon (IFN) Beta-001 | May 2005 | July 2005 |
| NCT02517788 | Completed | Phase 1 | Phase I BP Interferon (IFN) Beta-004 | May 2006 | July 2006 |
| NCT02525874 | Completed | Phase 3 | Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). | August 11, 2015 | April 23, 2018 |
| NCT02545868 | Completed | Phase 3 | A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis | October 27, 2015 | September 21, 2021 |
| NCT02555215 | Completed | Phase 3 | Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) | February 22, 2016 | September 24, 2018 |
| NCT02579681 | Completed | Phase 3 | Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 | April 30, 2014 | December 21, 2016 |
| NCT02598167 | Completed | Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition | December 7, 2015 | February 23, 2016 | |
| NCT02633033 | Completed | Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse | November 24, 2015 | May 9, 2019 | |
| NCT02637856 | Completed | Phase 3 | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) | February 11, 2016 | May 3, 2019 |
| NCT02652091 | Completed | Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction | February 5, 2016 | September 13, 2017 | |
| NCT02687919 | Completed | N/A | Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis | October 2012 | October 2014 |
| NCT02744222 | Completed | Phase 2/Phase 3 | Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis | August 10, 2017 | July 6, 2020 |
| NCT02746744 | Completed | Phase 3 | RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. | May 2016 | August 2021 |
| NCT02782858 | Completed | Phase 2 | Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS | April 2016 | December 2017 |
| NCT02861014 | Completed | Phase 3 | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) | September 9, 2016 | December 15, 2020 |
| NCT02988401 | Completed | Phase 1/Phase 2 | Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis | December 1, 2017 | December 17, 2021 |
| NCT03060759 | Completed | N/A | Light Therapy as Treatment for Fatigue in Multiple Sclerosis | April 1, 2017 | November 4, 2019 |
| NCT03085810 | Completed | Phase 3 | Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) | March 24, 2017 | April 27, 2023 |
| NCT03205280 | Completed | Clinical Decision Support System (CADIMS) for MS Diagnostic | October 11, 2017 | December 7, 2022 | |
| NCT03347370 | Completed | A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis | November 27, 2017 | July 31, 2019 | |
| NCT03385356 | Completed | Phase 4 | Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis | December 19, 2017 | April 30, 2018 |
| NCT03561402 | Completed | Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio) | December 1, 2016 | December 30, 2020 | |
| NCT03653585 | Completed | Cortical Lesions in Patients With Multiple Sclerosis | September 4, 2018 | September 3, 2020 | |
| NCT03679806 | Completed | N/A | Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis | May 2016 | September 2016 |
| NCT03689972 | Completed | Phase 3 | A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration | November 27, 2018 | July 24, 2023 |
| NCT03691766 | Completed | N/A | Photobiomodulation Therapy in Persons With Multiple Sclerosis | April 30, 2018 | September 23, 2019 |
| NCT03718026 | Completed | The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis | October 24, 2018 | November 19, 2018 | |
| NCT03768648 | Completed | N/A | Cognition and MRI Markers in MS Patients With Aubagio® Treatment | May 21, 2019 | February 23, 2023 |
| NCT03872583 | Completed | N/A | Understanding Magnetic Resonance Imaging in Multiple Sclerosis | March 15, 2019 | December 1, 2022 |
| NCT03942952 | Completed | PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes. | October 22, 2019 | June 30, 2023 | |
| NCT03975413 | Completed | Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis | September 25, 2018 | May 1, 2020 | |
| NCT04121221 | Completed | Phase 3 | A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS | September 19, 2019 | June 13, 2023 |
| NCT04211740 | Completed | Phase 2 | Phase II Clinical Trial of OCH-NCNP1 | December 6, 2019 | May 31, 2023 |
| NCT04221191 | Completed | Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP | August 19, 2019 | September 14, 2022 | |
| NCT04233970 | Completed | N/A | Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple Sclerosis | February 17, 2020 | May 5, 2023 |
| NCT04280484 | Completed | N/A | Acute Intermittent Hypoxia in Persons With Multiple Sclerosis | June 18, 2018 | December 30, 2019 |
| NCT04528121 | Completed | N/A | Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis | September 15, 2020 | December 30, 2020 |
| NCT04567264 | Completed | N/A | Wireless, Implantable Tibial Nerve Stimulator System for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis | August 26, 2020 | June 30, 2022 |
| NCT04580381 | Completed | Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort | September 1, 2020 | October 30, 2021 | |
| NCT04655222 | Completed | Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program | April 30, 2021 | October 15, 2021 | |
| NCT04756687 | Completed | Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera | March 10, 2021 | June 15, 2021 | |
| NCT04833673 | Completed | N/A | The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial | June 22, 2020 | March 15, 2021 |
| NCT05028634 | Completed | Phase 3 | Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy | October 27, 2021 | November 15, 2023 |
| NCT05029206 | Completed | Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden | May 5, 2021 | September 30, 2022 | |
| NCT05080270 | Completed | Early Phase 1 | Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis | September 21, 2020 | June 8, 2021 |
| NCT05218317 | Completed | Evaluation of Relapse Presence in Multiple Sclerosis | January 1, 2021 | January 1, 2022 | |
| NCT05345288 | Completed | N/A | Effect of Computerized Cognitive Training in Persons With MS | June 28, 2022 | October 21, 2022 |
| NCT05366036 | Completed | A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis | June 14, 2017 | January 14, 2022 | |
| NCT05438693 | Completed | Delayed Diagnosis of Multiple Sclerosis, Treatment Initiation and Non-adherence in Upper Egypt | June 1, 2020 | June 1, 2022 | |
| NCT05663853 | Completed | An Observational Biomarker Study in Multiple Sclerosis (MS) Patients | March 28, 2023 | April 30, 2024 | |
| NCT05684016 | Completed | N/A | Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM | December 2013 | December 2016 |
| NCT06345157 | Not yet recruiting | ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients | June 30, 2024 | June 30, 2026 | |
| NCT06413602 | Not yet recruiting | N/A | The Synergistic Effects of AIH and FES in Persons With MS | August 2024 | August 2027 |
| NCT05290688 | Not yet recruiting | N/A | Cellular microRNA Signatures in Multiple Sclerosis | September 15, 2022 | September 15, 2024 |
| NCT04236544 | Not yet recruiting | N/A | Patient Experiences of Multiple Sclerosis (PExMS) | January 1, 2024 | December 31, 2025 |
| NCT06389968 | Not yet recruiting | N/A | Light Stimulation to Improve Visual Function After Optic Neuritis in Persons With Multiple Sclerosis | May 2, 2024 | December 31, 2025 |
| NCT06325358 | Not yet recruiting | the EXPOSITION Study | April 15, 2024 | December 30, 2024 | |
| NCT04768777 | Not yet recruiting | N/A | Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis | December 1, 2024 | June 30, 2026 |
| NCT06390930 | Not yet recruiting | N/A | Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS | July 2024 | July 2027 |
| NCT06408259 | Not yet recruiting | Phase 3 | Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis | July 9, 2024 | July 13, 2036 |
| NCT05519553 | Not yet recruiting | N/A | Peer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis | November 1, 2022 | March 1, 2026 |
| NCT05658601 | Recruiting | A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) | July 14, 2023 | January 31, 2027 | |
| NCT03500328 | Recruiting | N/A | Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | May 2, 2018 | August 1, 2025 |
| NCT05752630 | Recruiting | Physical Activity, Sedentary Behaviour and Cardiometabolic Health in Multiple Sclerosis | January 30, 2023 | January 20, 2024 | |
| NCT05359653 | Recruiting | Phase 1/Phase 2 | Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy | August 1, 2023 | June 1, 2025 |
| NCT03283397 | Recruiting | Phase 3 | A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS | March 26, 2019 | July 1, 2024 |
| NCT05834855 | Recruiting | Phase 3 | Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS | April 2023 | May 2027 |
| NCT04448977 | Recruiting | Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI | May 6, 2021 | December 2024 | |
| NCT04458688 | Recruiting | Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis | November 20, 2021 | December 2030 | |
| NCT05335031 | Recruiting | A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®) | March 3, 2021 | November 30, 2029 | |
| NCT04565431 | Recruiting | Examining Effects of Tysabri on Cognitive Fatigue Using fMRI | March 19, 2021 | December 2024 | |
| NCT05920018 | Recruiting | N/A | Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis | October 2, 2023 | February 2025 |
| NCT03958877 | Recruiting | Phase 3 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | October 18, 2019 | May 20, 2027 |
| NCT05296161 | Recruiting | Phase 4 | B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis | April 20, 2022 | March 2026 |
| NCT03910738 | Recruiting | Phase 2 | TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis | October 29, 2019 | January 2027 |
| NCT05958381 | Recruiting | Phase 1/Phase 2 | Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation | October 18, 2023 | June 30, 2027 |
| NCT04625153 | Recruiting | Phase 2 | RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial | May 13, 2021 | December 2025 |
| NCT05648292 | Recruiting | The Relationships Between Personal Identity, Autobiographical Memory and Future Thinking in People With Multiple Sclerosis | December 7, 2022 | June 7, 2025 | |
| NCT05964829 | Recruiting | N/A | Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis | September 4, 2023 | June 2024 |
| NCT05615454 | Recruiting | N/A | Effect of Bio-electromagnetic Energy Regulation Therapy on Erectile Dysfunction in Patients With Multiple Sclerosis | February 28, 2023 | March 30, 2024 |
| NCT04002934 | Recruiting | Phase 2 | Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis | September 10, 2019 | June 30, 2025 |
| NCT06095271 | Recruiting | N/A | MultiSCRIPT-Cycle 1: Personalized Medicine in Multiple Sclerosis - Pragmatic Platform Trial Embedded Within the SMSC | February 5, 2023 | May 2027 |
| NCT06127095 | Recruiting | A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments | November 24, 2023 | October 30, 2024 | |
| NCT02903537 | Recruiting | Phase 1 | Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS) | July 6, 2017 | December 2023 |
| NCT04972929 | Recruiting | N/A | Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis | December 15, 2022 | December 30, 2024 |
| NCT04885894 | Recruiting | An Examination of Cognitive Fatigue Using Functional Neuroimaging | January 1, 2022 | December 2024 | |
| NCT05007483 | Recruiting | N/A | Efficacy of Diet on Quality of Life in Multiple Sclerosis | February 10, 2022 | December 1, 2026 |
| NCT05204459 | Recruiting | MS-ResearchBiomarkerS | November 11, 2021 | November 11, 2041 | |
| NCT05201638 | Recruiting | Phase 3 | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | January 12, 2022 | October 2032 |
| NCT05168384 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis | March 26, 2022 | June 2025 |
| NCT06129019 | Recruiting | N/A | the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Patient With Multiple Sclerosis | December 1, 2023 | June 1, 2024 |
| NCT06195800 | Recruiting | Biomarkers of aHSCT | August 9, 2023 | August 9, 2026 | |
| NCT06303024 | Recruiting | N/A | Targeting Subclinical Motor and Cognitive Impairment in Patients With Early Onset Multiple Sclerosis | June 14, 2023 | March 1, 2026 |
| NCT05510817 | Recruiting | N/A | Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns of Cognitive Status in RRMS | June 6, 2022 | June 6, 2026 |
| NCT05496881 | Recruiting | N/A | Exercise Effects in Multiple Sclerosis | June 15, 2022 | April 30, 2025 |
| NCT03387046 | Terminated | Phase 2 | A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS) | March 26, 2018 | January 11, 2019 |
| NCT03870763 | Terminated | Phase 3 | Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants | March 19, 2019 | July 21, 2022 |
| NCT00595920 | Terminated | Phase 2 | Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis | November 2007 | December 2008 |
| NCT01435993 | Terminated | Phase 1 | Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis | September 8, 2011 | January 23, 2012 |
| NCT01134627 | Terminated | Phase 2 | Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] | February 2006 | April 2011 |
| NCT02323269 | Terminated | Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) | May 2015 | March 2016 | |
| NCT02394782 | Terminated | Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL) | February 2015 | March 2016 | |
| NCT02418325 | Terminated | Phase 1/Phase 2 | A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | February 2015 | February 2017 |
| NCT02423083 | Terminated | Phase 1 | Oral Guanabenz for Multiple Sclerosis | April 21, 2015 | October 30, 2017 |
| NCT02427776 | Terminated | Phase 1/Phase 2 | A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis | January 2015 | August 2016 |
| NCT02580669 | Terminated | N/A | Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis | June 16, 2014 | February 13, 2017 |
| NCT05265728 | Terminated | Phase 3 | A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis | April 26, 2022 | May 27, 2024 |
| NCT02901106 | Terminated | Phase 4 | Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate | May 23, 2017 | October 17, 2017 |
| NCT01808482 | Terminated | Phase 1 | A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) | March 13, 2013 | August 6, 2013 |
| NCT03126760 | Terminated | Phase 4 | Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) | May 22, 2017 | July 14, 2020 |
| NCT03239860 | Terminated | Phase 2 | Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis | June 6, 2017 | November 14, 2018 |
| NCT03342638 | Terminated | Phase 3 | Maximizing Outcome of Multiple Sclerosis Transplantation | November 8, 2017 | October 9, 2019 |
| NCT05532163 | Terminated | Phase 4 | A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | January 23, 2023 | October 31, 2023 |
| NCT00780455 | Terminated | Phase 4 | Rehabilitation Study in MS Patients | October 2008 | September 2009 |
| NCT04979650 | Unknown status | Phase 2 | Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis | May 22, 2021 | October 23, 2023 |
| NCT05019248 | Unknown status | Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine | September 1, 2020 | April 30, 2022 | |
| NCT04993274 | Unknown status | Sensitivity of Motor Assessment in MS - a Prospective Cohort Study | February 20, 2019 | November 2022 | |
| NCT02769767 | Unknown status | Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis. | August 2012 | December 2016 | |
| NCT01453868 | Unknown status | Early Phase 1 | The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis | October 2011 | June 2012 |
| NCT04042415 | Unknown status | N/A | Calorie Restriction in Multiple Sclerosis | July 14, 2020 | September 2023 |
| NCT03610139 | Unknown status | N/A | Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients | May 21, 2018 | December 31, 2022 |
| NCT02369926 | Unknown status | Phase 2 | Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis | November 2014 | |
| NCT00411723 | Unknown status | Phase 1 | Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis | December 2006 | May 2009 |
| NCT05340985 | Unknown status | Phase 4 | Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis | July 2022 | December 2023 |
| NCT04121637 | Unknown status | N/A | To Investigate the Effect of Aerobic Exercise on Neurophysiological Values and Functionality in Individuals With Multiple Sclerosis. | October 21, 2019 | June 1, 2020 |
| NCT04450030 | Unknown status | Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis | August 1, 2018 | December 31, 2020 | |
| NCT00984984 | Unknown status | Phase 3 | Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses | March 2008 | June 2014 |
| NCT04073940 | Unknown status | N/A | Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis | August 29, 2019 | January 15, 2021 |
| NCT04260711 | Unknown status | N/A | Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS). | July 1, 2020 | January 1, 2024 |
| NCT04048577 | Unknown status | Phase 4 | A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab | July 3, 2019 | December 1, 2021 |
| NCT03401879 | Unknown status | N/A | Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis | February 1, 2018 | March 2023 |
| NCT03497468 | Unknown status | N/A | Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple Sclerosis | April 2018 | June 2018 |
| NCT02587806 | Unknown status | Phase 1/Phase 2 | A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | February 2015 | February 2017 |
| NCT02587715 | Unknown status | Phase 1/Phase 2 | A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | February 2015 | February 2017 |
| NCT04880577 | Withdrawn | Phase 2 | Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis | September 15, 2022 | February 14, 2025 |
| NCT02675413 | Withdrawn | Phase 4 | Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS | April 2016 | April 2016 |
| NCT04261556 | Withdrawn | N/A | tDCS to Enhance Cognitive Training in Multiple Sclerosis | November 21, 2019 | December 2024 |
| NCT05482542 | Withdrawn | N/A | Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis | January 1, 2023 | July 1, 2027 |
| NCT01071694 | Withdrawn | QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea | January 2011 | December 2012 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D020529